For the biotech industry, the FDA has a number of key decisions to make in the coming few months. Some of the most interesting drugs presently under review include Medivation, Inc. (NASDAQ:MDVN)’s enzalutamide (oncology), Biogen Idec Inc. (NASDAQ:BIIB)’s BG-12 (multiple sclerosis), United Therapeutics Corporation (NASDAQ:UTHR)’s oral Remodulin (treatment of pulmonary arterial hypertension), Gilead Sciences, Inc. (NASDAQ:GILD)’s Quad pill (HIV).
More candidates include Forest Labs’ linaclotide (constipation-predominant irritable bowel syndrome and chronic constipation), Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) and Bayer’s regorafenib (oncology).
Idenix Pharmaceuticals, Inc. (NASDAQ:IDIX) plunged -29.72% after the FDA put its hepatitis C drug on hold and closed at $5.84 with the total traded volume of 19.17 million shares. IDIX has market capitalization of 1.35 billion.
The last trading session observed a low of $5.40 and high of $6.24 during the day. The stock’s 52 week low is $4.30 and 52 week high is $15.25. Performance gauges illustrate that the stock has lost -31.78% within the last quarter.
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) declined -5.21% with the closing price of $7.82. The overall volume in the last trading session was 10.00 million shares. Its fifty two week range was $1.23-$13.50. The total market capitalization remained $1.70 billion.
ARNA is ahead of its 52 week low 535.77% and its last month price volatility remained 7.34%. Its beta coefficient was 0.20 with a target price of $11.80. Company’s current year earnings per share grew 29.52%. ARNA has positive year-to-date performance of 318.18%.
In the last trading session, Gilead Sciences, Inc. (NASDAQ:GILD) reported a fall of -2.21% and closed at $56.69 a day after analysts at Citigroup Inc. (NYSE:C) reaffirmed their buy rating on the stock. Its overall traded volume of 9.98 million shares was more than the average volume of 6.11 million.
GILD has outstanding shares of 756.57 million with the total market capitalization of 750.38 million and its beta value stands at 0.45 times. It has current ratio of 1.17 and its debt-to-equity ratio was 1.14.
Peregrine Pharmaceuticals (NASDAQ:PPHM) surged 7.58% and closed at $2.84 with the total traded volume of 5.86 million shares. PPHM has market capitalization of 295.85 million.
The last trading session observed a low of $2.68 and high of $3.09 during the day. The stock’s 52 week low is $0.39 and 52 week high is $3.21. Performance gauges illustrate that the stock has gained 545.45% within the last quarter.